Upstream is a partnership between Hammersmith & Fulham Council and Imperial College London, a result of an Industrial Strategy co-produced by the two organisations. They have been connecting, supporting and shining a light on the science, tech and creative sectors since 2018, all driven by the belief that local networks which facilitate collaboration and learning can accelerate the growth of organisations and places. Upstream envisions to make Hammersmith & Fulham an inclusive, thriving ecosystem of ambitious science, tech and creative organisations, with the White City innovation district a global beacon of growth through innovation.  Novartis is a life sciences business concerned with reimagining medicine to improve and extend people's lives, by using innovative science and technology to address some of society's most challenging healthcare issues. Novartis aims to discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible as well as reward those who invest their money, time and ideas in our company.

In June 2021, Upstream commenced a quarterly roundtable for the life sciences sector based in Hammersmith and Fulham. It brought together researchers, businesses, practitioners and academics in the life sciences space.  It was the first time that many of these senior leaders had met and the energy in the room, from the outset and particularly after networking sessions was palpable. Chaired by Professor Oscar Ces, Head of Chemistry at Imperial College London, attendees range from organisations including Novartis, the MRC London Institute of Medical Sciences (LMS), Hammersmith Hospital, Autolus, DNAE, Engitix and many more. The Roundtable centred around the role of White City as London's innovation cluster. The panelists discussed what can be done and improved to boost the image, infrastructure and opportunities of the White City. The participants also shared ideas for further enhancing collaboration within the City.

MediSieve is thankful for its long lasting partnership with Upstream and the opportunities it provides. The RoundTable not only offered a chance to share ideas and future visions but to network with the community in the White City which was hard to do during lockdowns.

More about Upstream https://www.move-upstream.org.uk

About Magnetic Blood Filtration 

MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.

About MediSieve

MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk